Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

About this update from Iovance Biotherapeutics, Inc.

[{"type":"image","alt":"Iovance Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Iovance Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":98,"url":"https://media.zenfs.com/en/globenewswire.com/fb47f4fbc477e50ab2663b1d46d1f520"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.v3WcxvLExw0gdNQeyFn2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fb47f4fbc477e50ab2663b1d46d1f520","width":300,"height":98}},"lazy":false},{"type":"text","content":"SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2025 financial results and corporate updates on Thursday, May 8, 2025.","length":362,"tagName":"p"},{"type":"text","content":"Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on May 8, 2025 at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/wi5b4tnt. The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com. The archived webcast will be available for one year.","length":429,"tagName":"p"},{"type":"text","content":"About Iovance Biotherapeutics, Inc.","length":35,"tagName":"p"},{"type":"text","content":"Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.","length":736,"tagName":"p"},{"type":"text","content":"Amtagvi® and its accompanying de...

More updates from Iovance Biotherapeutics, Inc.